Stool Transplant to Help Prevent Complications After Stem Cell Transplant
Tests a donor stool transplant in adults with blood cancers after stem cell transplant.
Plain-language title generated from the registry record
Registry title: Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
Key facts
- Where
- Amiens, Angers, Besançon, Clermont-Ferrand, Grenoble, Lille, Limoges, Lyon, Nancy, Nantes, Nice, Paris, Pessac, Poitiers, Rouen, Saint-Etienne, and Toulouse, FranceSee the 20 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a blood cancer in control who are having a stem cell transplant from a donor. It tests whether a faecal microbiota transplant helps prevent graft-versus-host disease.
- Age
- 18 years or older
- Sex
- Men and women can join.
- Disease stage
- A blood cancer that is under control, treated with a myelo-ablative allogeneic stem cell transplant using peripheral stem cells.
- Earlier treatment
- Not stated. Cord blood grafts are not accepted; any other type of donor is accepted.
Main reasons for not taking part
- Tumor progression at the time of the transplant
- Another progressive cancer, or one in the previous 3 years (basal cell carcinoma excepted)
- A serious uncontrolled disease at the same time, such as severe heart, kidney, liver or lung failure or severe sepsis
- Fecal incontinence
- Pregnancy
Read by machine on 12 November 2026.
Where in France
- Service d'Hématologie Clinique et Thérapie Cellulaire CHU Amiens Picardie - Site SudAmiens, FranceContact: Magalie Magalie, MDNot yet recruiting
- Service Maladies du sang CHU AngersAngers, FranceContact: Sylvie François, MDNot yet recruiting
- Hématologie clinique CHU BesançonBesançon, FranceContact: Etienne Daguindau, MDNot yet recruiting
- Plateforme d'Investigation Clinique / Centre d'Investigation Clinique - Inserm 1405, CHU Gabriel Montpied Clermont-FerrandClermont-Ferrand, FranceContact: Christian Dualé, MD, PhDTaking people
- Service de thérapie Cellulaire et d'Hématologie Clinique Adulte CHU Estaing - Clermont-FerrandClermont-Ferrand, FranceContact: Jacques-Olivier Bay, MD, PhDNot yet recruiting
- Service hématologie CHU GrenobleGrenoble, FranceContact: Claude-Eric Bulabois, MDNot yet recruiting
- Service des Maladies du sang Hôpital HURIEZ, CHRU de LilleLille, FranceContact: David Beauvais, MDNot yet recruiting
- Service de thérapie cellulaire et l'hématologie clinique adulte CHU LimogesLimoges, FranceContact: Pedro DE LIMA PRATA, MDTaking people
- Service d'Hématologie Centre Hospitalier Lyon SudLyon, FranceContact: Marie-Virginie Larcher, MDNot yet recruiting
- Service d'Hématologie et de Médecine interne Hôpital Brabois CHRU NancyNancy, FranceContact: Marie-Therese Rubio, MDNot yet recruiting
- Service d'Hématologie Clinique CHU NantesNantes, FranceContact: Patrice Chevallier, MDNot yet recruiting
- Service d'hématologie clinique, département de greffe de moelle CHU NiceNice, FranceContact: Michel Loschi, MDNot yet recruiting
- Service d'Hématologie Adultes Hôpital NeckerParis, FranceContact: felipe Suarez, PU-PHTaking people
- Service d'Hématologie clinique Hôpital Pitié-SalpêtrièreParis, FranceContact: Stéphanie Nguyen, MD, PhDNot yet recruiting
- Service d'hématologie greffe Hôpital St LouisParis, FranceContact: Marie Robin, MDNot yet recruiting
- Hématologie clinique et thérapie cellulaire Hôpital Haut-LévèquePessac, FranceContact: Carmen Botella Garcia, MDNot yet recruiting
- Service d'hématologie greffe Hôpital St LouisPoitiers, FranceContact: Deborah Desmier, MDNot yet recruiting
- Département d'hématologie CAC RouenRouen, FranceContact: Anne-Lise Menard, MDNot yet recruiting
- Hématologie clinique Institut de Cancérologie de la LoireSaint-Etienne, FranceContact: Emmanuelle Tavernier, MDNot yet recruiting
- IUC T - OncopôleToulouse, FranceContact: Anne Huynh, MDNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Hospital, Clermont-Ferrand
- Trial code
- NCT04935684
- Record updated
- 21 September 2026
- Original description
The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications and particularly Graft versus Host Disease (GvHD).Read full original descriptionShow less
Faecal Microbiota Transplantation for Prevention of Graft-versus-host Sisease After Allogeneic Stem Cell Transplantation for Haematological Malignancies
The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications and particularly Graft versus Host Disease (GvHD).
The hypothesis of this study is that allogeneic FMT may improve outcomes of these patients.
Inclusion: Patient aged 18 or over; Men and women; Patients affiliated with a social-security organization; Patients undergoing a myelo-ablative allo-HSCT for a controlled haematologic malignant disease, with peripheral stem cells, whatever the type of donor (except cord blood); Signed and dated informed consent.
Exclusion: Medical history of another progressive cancer or occurrence in the 3 previous years (excluding basal cell carcinoma); Presence of a simultaneous serious and uncontrolled disease (severe cardiac, renal, hepatic or respiratory failure, severe sepsis); Status of tumor progression at the time of allo-HSCT; Inability to understand the protocol (linguistic barrier, cognitive difficulties); Fecal incontinence; Participation in another clinical trial studying an allograft procedure including the type of graft, the type of immunosuppression, a preventive or a curative treatment of GvHD, or studying the effectiveness of a FMT in another indication; Pregnant women; Patient under guardianship, curatorship or protection of justice.